A randomized trial comparing the safety, adherence, and pharmacodynamics profiles of two doses of sodium bicarbonate in CKD: the BASE pilot trial
Background Oral sodium bicarbonate (NaHCO 3) may preserve kidney function in CKD,
even if initiated when serum bicarbonate concentration is normal. Adequately powered trials
testing this hypothesis have not been conducted, partly because the best dose for testing is
unknown. Methods This multicenter pilot trial assessed the safety, tolerability, adherence,
and pharmacodynamics of two doses of NaHCO 3 over 28 weeks in adults with eGFR 20–44
or 45–59 ml/min per 1.73 m 2 with urinary albumin/creatinine (ACR)≥ 50 mg/g and serum …
even if initiated when serum bicarbonate concentration is normal. Adequately powered trials
testing this hypothesis have not been conducted, partly because the best dose for testing is
unknown. Methods This multicenter pilot trial assessed the safety, tolerability, adherence,
and pharmacodynamics of two doses of NaHCO 3 over 28 weeks in adults with eGFR 20–44
or 45–59 ml/min per 1.73 m 2 with urinary albumin/creatinine (ACR)≥ 50 mg/g and serum …
